EGFR

CASE SELECTION 1: Long-Term Survival with EGFR-TKI-Resistence in Stage 4 NSCLC

In this first collection, we discuss EGFR-TKI-resistant in stage 4 NSCLC. Despite negative prognosis statistics, many patients have achieved long-term survival by undergoing multiple lines of treatment—an option not always explicitly detailed in standard treatment guidelines (You can download FREE HERE). This underscores the importance of self-advocacy and proactive discussions with your doctor to push for personalized treatment plans.

CASE SELECTION 1: Long-Term Survival with EGFR-TKI-Resistence in Stage 4 NSCLC Read More »

UNDERSTANDING DATO-DXd CLINICAL TRIAL RESULTS IN NSCLC

This document summarizes key clinical trial findings for Dato-DXd in non-small cell lung cancer (NSCLC), focusing on results from two studies: the Phase II TROPION-Lung05 and the Phase III TROPION-Lung01 trials. Special attention is given to the outcomes in patients with EGFR-mutated disease, including a deeper analysis of Dato-DXd’s potential role in this molecular subgroup.

UNDERSTANDING DATO-DXd CLINICAL TRIAL RESULTS IN NSCLC Read More »